Piramal and NP2 Partner to Stabilize Domestic Cyclophosphamide Supply

Cyclophosphamide remains a vital treatment for cancers ranging from breast cancer to retinoblastoma. Currently, the U.S. market relies heavily on overseas manufacturers, with two foreign entities controlling 92% of sales. According to Q2 IQVIA data, one provider accounts for nearly 70% of the 200 mg ready-to-use solution market, leaving the U.S. vulnerable to the supply disruptions already affecting patients in the EU and Canada.

To mitigate these risks, NP2 is leveraging Piramal’s Lexington facility, which is currently undergoing an $85 million expansion to boost production capacity. Telly Athanasopoulos, NP2's Head of Manufacturing, emphasized that the shift to domestic production is a strategic move to ensure stable pricing and availability for doctors and patients. Terri Miller, Executive Director of NP2, noted that the initiative targets systemic vulnerabilities in global manufacturing consolidation. The project is expected to reach the commercial market by mid-2028, offering an alternative to the current reliance on international supply chains.